The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers
Name: Esomeprazole
Name: Placebo
Description: The absence of gastric and/or duodenal ulcer throughout the treatment period
Measure: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period Time: each visit up to 24 weeksDescription: The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment
Measure: Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment Time: up to 4 weeksDescription: The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment
Measure: Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment Time: up to 12 weeksAllocation: Randomized
Parallel Assignment
There is one SNP
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period. --- D961H ---